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Abstract
Cancer progression towards metastasis follows a defined sequence of events described as
the metastatic cascade. For extravasation and transendothelial migration metastatic cells in-
teract first with endothelial cells. Yet the role of endothelial cells during the process of metas-
tasis formation and extravasation is still unclear, and the interaction between metastatic and
endothelial cells during transendothelial migration is poorly understood. Since tumor cells are
well known to express TGF-β, and the compact endothelial layer undergoes a series of
changes during metastatic extravasation (cell contact disruption, cytoskeletal reorganization,
enhanced contractility), we hypothesized that an EndMTmay be necessary for metastatic
extravasation. We demonstrate that primary cultured rat brain endothelial cells (BEC) under-
go EndMT upon TGF-β1 treatment, characterized by the loss of tight and adherens junction
proteins, expression of fibronectin, β1-integrin, calponin and α-smooth muscle actin (SMA).
B16/F10 cell line conditioned and activated medium (ACM) had similar effects: claudin-5
down-regulation, fibronectin and SMA expression. Inhibition of TGF-β signaling during B16/
F10 ACM stimulation using SB-431542 maintained claudin-5 levels and mitigated fibronectin
and SMA expression. B16/F10 ACM stimulation of BECs led to phosphorylation of Smad2
and Smad3. SB-431542 prevented SMA up-regulation upon stimulation of BECs with A2058,
MCF-7 and MDA-MB231 ACM as well. Moreover, B16/F10 ACM caused a reduction in trans-
endothelial electrical resistance, enhanced the number of melanoma cells adhering to and
transmigrating through the endothelial layer, in a TGF-β-dependent manner. These effects
were not confined to BECs: HUVECs showed TGF-β-dependent SMA expression when stim-
ulated with breast cancer cell line ACM. Our results indicate that an EndMTmay be neces-
sary for metastatic transendothelial migration, and this transition may be one of the potential
mechanisms occurring during the complex phenomenon known as metastatic extravasation.
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Introduction
Endothelial-mesenchymal transition (EndMT) is an embryonic program necessary for organ
development. Despite being normally dormant in adult organisms, this mechanism can be re-
activated during several pathological conditions, such as cancer and fibrosis. At cellular and
molecular level EndMT is regulated by similar factors and signaling pathways under both phys-
iological and pathological conditions. EndMT was first described during heart development
[1]. During cancer, EndMT contributes to the formation of cancer-associated fibroblasts [2],
and it was found to be an important mechanism during renal and cardiac fibrosis [3, 4]. Re-
cently, EndMT was found to be involved in the formation of cerebral cavernous malformations
in CCM1 deficient mice [5].
EndMT is related to epithelial-mesenchymal transition, which represents a highly similar
mechanism characterized by analogous sequence of events. During EndMT endothelial cells
lose their endothelial markers and endothelial cell contacts (e.g., VE-cadherin), express fibro-
blast-specific and mesenchymal proteins (e.g., FSP1, PAI-1), start to synthesize extracellular
matrix (e.g., fibronectin), and ultimately differentiate into α-smooth muscle actin (SMA)-posi-
tive myofibroblasts. EndMT follows a sequentially orchestrated, defined chronology: down-
regulation of the endothelial program, activation of the mesenchymal-fibrogenic program, and
finally the activation of the myogenic program [6, 7].
Metastasis formation is responsible for the overwhelming majority of cancer-related mortal-
ity [8]. Cancer progression towards metastasis follows a defined sequence of events described
as the metastatic cascade. First, cells from the primary tumors invade the local extracellular ma-
trix, then intravasate into the lumina of blood vessels. Following the transport through the vas-
culature metastatic cells extravasate into the surrounding tissue, form micrometastasis in the
target tissue and, by reinitiating their proliferative program, generate macroscopic metastases
[9, 10]. Despite the fact that the metastatic cascade is a highly inefficient process, large numbers
of circulating tumor cells can undergo extravasation [11].
In order to overcome physical barriers extravasating tumor cells secrete factors that reduce
endothelial barrier function. Tumor cells are also well known to express TGF-β1 [12, 13],
whereas malignant melanoma patients present elevated plasma TGF-β1 and TGF-β2 levels [14],
breast cancer cell lines also expressing different TGF-β isoforms [15]. In the context of metastat-
ic progression, serum TGF-β1 levels showed a sudden elevation at the time point of metastasis
initiation [16]. Extravasation takes place mainly through paracellular transendothelial migration
(TEM). Cancer cells activate signaling pathways in endothelial cells via secreted factors to dis-
rupt VE-cadherin complexes. This enables the interendothelial junctional complex disintegra-
tion, and metastatic cells migrate through the endothelial cell junction openings [17, 18].
The majority of intracranial tumors are brain metastases, primary brain tumors represent-
ing only about 10% of new cases of intracranial malignancies [19]. Brain metastases mainly
originate from lung cancer, breast cancer and malignant melanoma [20]. Since the central ner-
vous system (CNS) lacks a lymphatic system, metastatic cells can only reach the brain through
the blood stream. In order to invade the CNS parenchyma, cancer cells need to pass the blood-
brain barrier (BBB), which represents the tightest endothelial barrier in the organism. In spite
of this, the role of endothelial cells during the process of metastasis formation and extravasa-
tion is still unclear, and the interaction between metastatic and endothelial cells during trans-
endothelial migration is poorly understood [21]. During metastasis endothelial cells undergo
expressional changes and signaling events corresponding to a transition towards a mesenchy-
mal phenotype: rearrangements in cell surface and cell contact proteins or enhanced contractil-
ity. Therefore, we hypothesized that EndMT is necessary for extravasation of metastatic cells.
Here we demonstrate that primary brain endothelial cells (BECs) undergo EndMT upon TGF-
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β1 treatment in vitro, and activated cancer cell line conditioned medium is sufficient to induce
EndMT of BECs in a TGF-β-dependent manner. Moreover, stimulation of endothelial cells
with activated cancer cell line conditioned medium resulted in TGF-β-dependent decrease of
transendothelial electrical resistance, increase in adhesion between metastatic and endothelial
cells and enhanced transendothelial migration of melanoma cells. These effects were not con-
fined to brain endothelial cells; human umbilical vein endothelial cells (HUVEC) could also
undergo EndMT under similar conditions. Our results indicate that an EndMT may be neces-
sary for metastatic transendothelial migration, and this transition may be one of the potential
mechanisms occurring during the complex phenomenon known as metastatic extravasation.
Materials and Methods
Cell culture and treatments
Primary rat brain endothelial cells (RBECs) were isolated from two week oldWistar rats (Toxi-
Coop, Budapest, Hungary), as described previously [22]. Cerebral cortices were disaggregated
and digested in two steps with collagenase (Sigma, Budapest, Hungary) and collagenase/dispase
(Roche, Budapest, Hungary) followed by centrifugation for 10 min at 1000xg on Percoll (Sigma)
gradient; microvessel fragments were collected and plated onto fibronectin/collagen-coated
dishes. Endothelial cell outgrowth was cultured in DMEM/F12 (Life Technologies, Budapest,
Hungary) containing 10% plasma-derived serum (PDS, First Link, Wolverhampton, UK), bFGF,
heparin, and insulin-transferrin-selenite (Sigma). Isolation of primary cerebral endothelial cells
was carried out in strict accordance with the national and international recommendations for the
care and use of laboratory animals. The protocol was reviewed and approved by the Regional An-
imal Health and Food Control Station of Csongrád County (Permit Number: XVI/2980/2012).
Human umbilical vein endothelial cells (HUVECs) were isolated as described previously
[23]. Human umbilical cord veins were obtained from the 2nd Department of Obstetrics and Gy-
naecology, Semmelweis University, after obtaining written informed consent for use of these
samples in research approved by the Semmelweis University Regional and Institutional Com-
mittee of Science and Research Ethics, Budapest, Hungary (TUKEB 126/2014). Briefly, HUVECs
were separated by collagenase treatment (Sigma). Cells were seeded onto 0.5% gelatin-coated
flasks (Sigma) and cultured in M199 medium (Sigma) supplemented with 15% fetal bovine
serum (FBS, Life Technologies), 100 IU/ml penicillin (Life Technologies), 100 μg/ml streptomy-
cin (Life Technologies), 7.5 IU/ml heparin (Merckle, Ulm, Germany), 2 ng/ml epidermal growth
factor (R&D Systems, Abington, UK), and 250 pg/ml β-endothelial cell growth factor (R&D Sys-
tems), referred to as complete medium. Cells from passages 2–4 were used for experiments.
B16/F10 murine melanoma cells were kept in RPMI medium (Sigma) supplemented with
5% FBS (Lonza, Basel, Switzerland) and Glutamax (Life Technologies). A2058 human melano-
ma cells were maintained in MEM (Sigma) supplemented with 5% FBS (Lonza) and Glutamax
(Life Technologies). SK-BR3, MCF-7 and MDA-MB231 human breast cancer cells were grown
in DMEM (Sigma) supplemented with 10% FBS (Lonza). Cells were grown at 37°C under a hu-
midified atmosphere containing 5% CO2.
TGF-β1 (Sigma) treatments were carried out as specified at the individual experiments
(10 ng/ml or vehicle for controls).
To obtain cancer cell line conditioned medium for RBECs, serum-free DMEM/F12 medium
was collected after 24 hrs. Latent TGF-β was heat activated (80°C, 10 min). PDS was supple-
mented before adding non activated or activated conditioned medium to RBECs. To obtain
cancer cell line conditioned medium for HUVECs, serum-free M199 medium was collected
after 24 hrs. Latent TGF-β was heat activated (80°C, 10 min). FBS was supplemented before
adding non activated or activated conditioned medium to HUVECs.
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Antibodies and reagents
The following commercially available antibodies were used: claudin-5 (Zymed/Life Technolo-
gies), occludin (Transduction Laboratories, Franklin Lakes, NJ, USA), VE-cadherin (Cell Sig-
naling, Danvers, MA, USA), N-cadherin (Transduction Laboratories), β1-integrin (Santa Cruz
Biotechnologies, CA, USA), fibronectin (Sigma), calponin (DAKO, Glostrup, Denmark), SMA
(Sigma), α-tubulin (Sigma), SRF (Santa Cruz Biotechnologies), phospho-Smad2/Smad3 (Cell
Signaling), Smad2/3 (Cell Signaling). Peroxidase-conjugated anti-mouse and anti-rabbit sec-
ondary antibodies were obtained from Cell Signaling. Cy3-labeled anti-mouse and Cy3-labeled
anti-rabbit antibodies were obtained from Jackson ImmunoResearch (Newmarket, UK). SB-
431542 was purchased from Sigma. Y-27632 was obtained from Tocris (Bristol, UK). For in-
hibitor studies control cells were treated with vehicle.
Immunofluorescence microscopy
Cells were fixed with ethanol/acetic acid (95/5) at −20°C for 5 min. After blocking with 3%
BSA for 30 min, samples were incubated with primary antibodies. The staining was visualized
using Cy3-conjugated secondary antibodies. Nuclear staining of the cells was carried out using
Hoechst 33342 (Sigma). Images were recorded by a Nikon Eclipse TE2000U photomicroscope
with epifluorescent capabilities connected to a digital camera (Spot RT KE).
Western Blot
Cells were scraped into RIPA lysis buffer. Protein concentration was determined using the
BCA Protein Assay (Pierce Thermo Scientific, Rockford, IL). Samples were mixed in a 1:1 ratio
with two times Laemmli buffer and boiled for 5 minutes. Equal amounts of protein were sepa-
rated on 12% SDS-polyacrylamide gel and transferred to nitrocellulose membranes (Bio-Rad,
Budapest, Hungary). Membranes were blocked with Tris-buffered saline, containing 0.1%
Tween 20 and 5% skim milk for an hour, and then incubated overnight with the primary anti-
body (in Tris-buffered saline-Tween 20 plus 0.5% skim milk), extensively washed, and incubat-
ed with the corresponding peroxidase-conjugated secondary antibody. Blots were visualized by
the electrochemiluminescence detection system (Thermo Scientific, Waltham, MA, USA).
Quantification results for N-cadherin are presented as mean ± SE.
Transendothelial Electrical Resistance Measurement (TEER)
RBECs were grown on collagen/fibronectin-coated semipermeable filters (0.4 μm pore size,
1.12 cm2, Costar Corning Transwell Clear, Sigma). After reaching confluence, the endothelial
monolayer was supplied with 550 nM hydrocortisone, 250 μMCPT-cAMP (Sigma) and 17.5
μMRO-201724 (Roche) and placed into the wells of the CellZscope instrument (nanoAnaly-
tics, Münster, Germany) containing astrocyte conditioned medium. Treatments were applied
after TEER had reached plateau. TEER was recorded at the indicated time points.
Adhesion experiments
RBECs were grown in 24-well plates. After reaching confluence RBECs were treated with TGF-
β1, B16/F10 conditioned media (B16/F10-CM) or B16/F10 activated conditioned media (B16/
F10-ACM) in the presence or absence of SB-431542 for 5 hrs. B16/F10 melanoma cells were
fluorescently labeled using Oregon Green 488 carboxylic acid diacetate succinimidyl ester (Life
Technologies) using the protocol supplied by the manufacturer. 5x104 melanoma cells/well
were loaded onto the endothelial monolayer in serum-free medium and left for 70 min. After
washing cells were fixed using ethanol/acetic acid (95/5) at-20°C for 5 min. Melanoma cells
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attached to endothelial cells were photographed and counted using the Image-Pro Plus soft-
ware (Media Cybernetics, Rockville, MD, USA).
Transmigration of melanoma cells through BECmonolayers
RBECs were cultured until confluence in 12 well plates and treated with TGF-β1 or ACM for 5 h.
B16/F10melanoma cells (2 x 104/well) were plated onto the monolayer. For inhibitor studies, cells
were preincubated with SB-431542 for 60 minutes. Cells were monitored over 10 h and phase
contrast images were taken using an Andor NEO sCMOS camera (Andor Technology, Belfast,
UK) connected to the Nikon Eclipse Ti-E inverted microscope equipped with a home built incu-
bator set to 37°C. Photographs were made every 5 min and transmigrated cells were counted.
Gene microarray data analysis
For this a set of gene expression profiles was downloaded from Gene Expression Omnibus
(GEO) of the National Center for Biotechnology Information (NCBI). Data was derived from
HUVECs and 1205Lu melanoma cells grown alone or in co-culture (accession number:
GSE8699). Gene expression levels between HUVECs grown alone and HUVECs co-cultured
with the melanoma cells were analyzed. EndMT marker gene expression levels were compared
in the two datasets. Genes with a detection p-value<0.05 were considered if presenting a mini-
mum fold change threshold of 1.5.
Results
1. TGF-β1 induces EndMT of cerebral endothelial cells
To assess whether primary rat BECs (RBEC) could undergo transition towards a mesenchymal
phenotype, RBECs were treated with 10 ng/ml of TGF-β1, and the subsequent changes were ex-
amined by immunofluorescence microscopy andWestern blot. First, to visualize potential loss
of cell-cell contacts, cells were immunostained for claudin-5 and VE-cadherin. In control cells
claudin-5 and VE-cadherin accumulated in the cell membrane, clearly delimitating neighbor-
ing cells. This peripheral staining disappeared 48 hrs after TGF-β1 treatment and RBECs be-
came negative for claudin-5 and VE-cadherin expression (Fig. 1a).
As loss of cell contacts is a common feature of endothelial-mesenchymal transition, the effects
of TGF-β1 treatment with regard to specific EndMTmarkers was examined. Similarly to EMT,
EndMTmarkers can be classified according to the different programs activated during transi-
tion: down-regulation of the endothelial program characterized by the loss of tight and adherent
junctions, activation of the mesenchymal-fibroblast program as evidenced by mesenchymal
marker expression, and the activation of the myogenic program ensuring enhanced contractility.
TGF-β1 treatment induced a severe decline in tight and adherent junction protein expres-
sion. TGF-β1 induced down-regulation of claudin-5, occludin-1 and VE-cadherin expression.
Concomitantly TGF-β1 induced β1-integrin expression (Fig. 1b). Endothelial cells are known
to express N-cadherin, yet upon TGF-β1 treatment RBECs exhibited a significant increase in
N-cadherin expression (Fig. 1c). Following TGF-β1 treatment RBECs started expressing fibro-
nectin (Fig. 1d). Finally, we observed de novo expression of calponin and α-smooth muscle
actin (SMA), myogenic expression patterns ensuring enhanced endothelial cell contractility
(Fig. 1e, 1f). SMA expression, an established myofibroblast marker, reflects the last stage of
EndMT. Based on these data we concluded that TGF-β1 treatment induces EndMT in RBECs.
To examine the specificity of TGF-β1 treatment we used SB-431542, a well-known TGF-β
receptor I kinase inhibitor. Treatment of cells with the inhibitor prevented TGF-β1 induced
SMA and calponin expression (Fig. 2a). The Rho-SRF (Serum Response Factor) pathway is a
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Fig 1. TGF-β1 induces EndMT in primary rat BECs. (a) BECs were subjected to 48 hrs TGF-β1 treatment,
then fixed and stained for claudin-5 and VE-cadherin. Control cells showed claudin-5 and VE-cadherin at
their intercellular borders, which was depleted in TGF-β1 treated cells (400x magnification). BECs were
treated with TGF-β1 for 48 hrs, and were analyzed for endothelial, mesenchymal and myogenic marker
expression byWestern blot. TGF-β1 treatment led to the (b) down-regulation of tight and adherens junction
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central regulator of SMA expression during EMT. The following experiments were carried out
to determine whether this pathway could be relevant for SMA expression during EndMT of
RBECs. Cells were pretreated with the specific Rho kinase inhibitor Y-27632. Y-27632 pre-
vented TGF-β1 induced SMA expression (Fig. 2b). Moreover, TGF-β1 induced a marked
nuclear translocation of SRF in RBECs (Fig. 2c), a translocation necessary for CArG-
box dependent protein expression. These results indicated that Rho kinase is required for
mediating TGF-β1-induced effects.
protein expression (claudin-5, occludin, VE-cadherin), it induced β1-integrin expression and (c) and led to a
marked increase in N-cadherin expression (2.18±0.48 fold based on three independent experiments, where
N-cadherin expression increased 2.11, 1.52 and 2.89 fold respectively, as compared to controls). TGF-β1
treated cells showed a robust expression of fibronectin (d), SMA and calponin (e). SMA expression was
observed by immunofluorescence microscopy (400x magnification) under similar conditions as well (f).
doi:10.1371/journal.pone.0119655.g001
Fig 2. TGF-β1 induced SMA expression in BECs requires TGFβR and ROCK. TGF-β1 treatment leads to SRF nuclear translocation. (a)Cells were
preincubated with 10 μMSB-431542 for 60 min and then treated with TGF-β1 for 48 hrs in the presence of SB-431542, and analyzed byWestern blot. TGF-
β1 induced SMA and calponin expression was mitigated in SB-431542 treated cells. (b) Cells were pretreated with 10 μMY-27632 for 60 min and then
treated with TGF-β1 for 48 hrs in the presence of the inhibitor, and analyzed byWestern blot. TGF-β1 induced SMA expression was inhibited in the presence
of Y-27632. (c) BECs were subjected to 24 hrs of TGF-β1 treatment, then were fixed and stained for SRF. Specimens were analyzed by
immunofluorescence microscopy. Control cells expressed SRFmainly in their cytoplasm, whereas TGF-β1 treatment led to its nuclear translocation (400x
magnification).
doi:10.1371/journal.pone.0119655.g002
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2. Cancer cell line conditioned/activated medium induces
TGF-β-dependent EndMT in brain endothelial cells
Pathologic EndMT was described during fibrosis and cancer associated fibroblast differentia-
tion, yet it is less plausible that RBEC EndMT would be relevant for these pathophysiological
mechanisms. When we searched for a potential relevance of our findings, we turned our atten-
tion towards the interaction between metastatic and endothelial cells. Cancer cells are known
to express latent TGF-β [24]. EndMT induced by metastatic cells might be a key step for extrav-
asation through the BBB during metastatic colonization of the brain, but also during extravasa-
tion to other target tissues. To assess whether metastatic cells are able to induce RBEC EndMT,
RBEC medium was conditioned with B16/F10 murine melanoma cells, TGF-β was then heat-
activated and RBECs were stimulated with B16/F10 conditioned medium (CM) or condi-
tioned/activated medium (ACM). Stimulated cells exhibited features of EndMT: similarly to
TGF-β1 treatment, B16/F10 ACM, but not CM, down-regulated claudin-5 (Fig. 3a) levels, and
induced the expression of fibronectin (Fig. 3b) and SMA (Fig. 3c). Besides TGF-βmetastatic
and tumor cells are known to express a multitude of growth factors. To show that EndMT in-
duced by cancer cell ACM is mediated by TGF-β signaling, phosphorylation status of Smads
was addressed. Similarly to TGF-β1, RBECs responded with phosphorylation of Smad2 and
Smad3 when stimulated with B16/F10 ACM for 30 minutes (Fig. 3d). To show that RBEC
EndMT induced by metastatic cell ACM is occurring through TGF-β, cells were treated with
SB-431542 to interfere with TGF-β receptor signaling. SB-431542 treatment of RBECs pre-
served claudin-5 levels upon stimulation with B16/F10 ACM (Fig. 3e). The presence of the in-
hibitor prevented fibronectin and SMA expression of RBECs when stimulated with B16/F10
ACM (Fig. 3f and 3g).
Next A2058 humanmetastatic melanoma cells were used to condition the RBECmedium.
RBECs were then treated with A2058 ACM, which induced SMA expression in the cells. SMA ex-
pression was prevented in the presence of SB-431542 indicating that A2058 ACM-induced SMA
expression was also dependent on TGF-β expressed by A2058 cells. Further, A2058 ACM induced
VE-cadherin down-regulation, an effect diminished by the presence of SB-431542 (Fig. 4a).
Finally, to determine whether the effects of metastatic cell ACM are confined to melanoma,
or other cancer cell lines could also induce RBEC EndMT, RBEC medium was conditioned
with MCF-7 and MDA-MB231 human metastatic breast cancer cells. Following the activation
step, MCF-7 ACM induced SMA and fibronectin expression in RBECs, and this effect was mit-
igated in the presence of the TGF-β inhibitor SB-431542 (Fig. 4b). Similarly, MDA-MB231
ACM induced SMA expression and reduced VE-cadherin levels in RBECs, and these effects
could be prevented in the presence of the TGF- β inhibitor SB-431542 (Fig. 4c).
3. Metastatic cell conditioned/activated medium reduces
transendothelial electric resistance in RBECs in a TGF-β dependent
manner
To test whether TGF-β1 or B16/F10 ACM could induce biomechanical changes and im-
pairment of endothelial junctions that would reduce barrier function and integrity, transen-
dothelial electric resistance (TEER) was measured in RBECs. A marked decrease in TEER was
observed already after 2 hrs of TGF-β1 and B16/F10 ACM treatment, and TEER declined fur-
ther 3 hrs and 24 hrs after treating RBECs. Importantly, pretreatment of RBECs with SB-
431542 preserved TEER when stimulated with TGF-β1 or B16/F10 ACM (Fig. 5a). These
results showed that TGF-β1 or B16/F10 ACM decreased electric resistance indicating disrup-
tion in the RBEC monolayer integrity, and the decline of TEER induced by B16/F10 ACM was
TGF-β dependent.
Endothelial-Mesenchymal Transition during Metastatic Extravasation
PLOS ONE | DOI:10.1371/journal.pone.0119655 March 5, 2015 8 / 19
Fig 3. Activated B16/F10 conditionedmedium induces EndMT in BECs through TGF-β signaling. PDS-free BECmedium was conditioned with B16/
F10 cells for 24 hrs, heat activated and then supplemented with PDS. Conditioned medium (CM) or heat-activated conditioned medium (ACM) was then used
to stimulate BECs for 48 hrs, samples being analyzed byWestern blot. Similarly to the parallel TGF-β1 treatments, ACM induced EndMT of BECs as
evidenced by the reduction of claudin-5 protein levels (a), as well as by the expression of fibronectin (b) and SMA (c). (d) BECs were stimulated with TGF-β1
or B16/F10 ACM for 30 minutes. Both stimuli induced phosphorylation of Smad2 and Smad3. Cells were pre-treated with 10 μMSB-431542 for 60 min and
Endothelial-Mesenchymal Transition during Metastatic Extravasation
PLOS ONE | DOI:10.1371/journal.pone.0119655 March 5, 2015 9 / 19
then treated with conditioned medium (CM) or heat-activated conditioned medium (ACM), in the presence of the inhibitor. Samples were analyzed by
Western blot. SB-431542 treatment of RBECs preserved claudin-5 levels (e). The presence of the inhibitor prevented fibronectin (f) and SMA (g) expression
of RBECs when stimulated with B16/F10 conditioned/activated medium.
doi:10.1371/journal.pone.0119655.g003
Fig 4. Activated cancer cell conditioned medium induces SMA expression through TGF-β signaling in RBECs. PDS-free BECmedium was
conditioned with A2058 humanmelanoma, MCF-7 human breast cancer or MDA-MB231 human breast cancer cells for 24 hrs. A half of the conditioned
media were subjected heat activation, and then both conditioned (CM) and activated conditioned media (ACM) were supplemented with PDS. Cells were pre-
treated with 10 μMSB-431542 for 60 min and then treated with CM or ACM, in the presence of SB-431542. Samples were analyzed byWestern blot. SB-
431542 inhibited A2058 ACM induced SMA expression and VE-cadherin down-regulation (a), as well as MCF-7 ACM induced SMA and fibronectin
expression (b). SB-431542 prevented MDA-MB231 ACM induced SMA expression and VE-cadherin down-regulation (c).
doi:10.1371/journal.pone.0119655.g004
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Fig 5. TGF-β1 and activated B16/F10 conditioned mediummodulate TEER, melanoma-endothelial cell
adhesion and transendothelial migration of melanoma cells. (a) TGF-β1 and activated B16/F10
conditioned medium reduce TEER of RBECs. Both TGF-β1 and activated B16/F10 conditioned medium
caused a significant, time dependent decline of the transendothelial electric resistance (TEER) of the RBEC
monolayer. SB-431542 (60 min) pretreatment and treatment of RBECs inhibited or reduced the decline of
Endothelial-Mesenchymal Transition during Metastatic Extravasation
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4. Metastatic cell conditioned/activated medium enhances adhesion of
metastatic cells to endothelial layers
A critical step during metastatic extravasation and transendothelial migration is the adhesion
of metastatic cells to the endothelial layer. We wished to assess whether TGF-β could influence
the adhesion of metastatic melanoma cells to BECs. The number of attached melanoma cells
doubled when endothelial cells were pre-treated with TGF-β1, as compared to the control ad-
hered cell numbers. Further, B16/F10 CM did not affect the number of adhered cells; however,
when B16/F10 CM was heat activated, the number of adhered melanoma cells was in the range
of the cells adhered upon treatment of BECs with TGF-β1. Importantly, this increase in mela-
noma-endothelial cell adherence could be reduced in the presence of SB-431542, indicating
that the increased adherence between melanoma and endothelial cells is TGF-β dependent
(Fig. 5b).
5. TGF-β1 and cancer cell ACM enhance transendothelial migration of
melanoma cells
To test whether the increase in the number of melanoma cells attached to the endothelium is
accompanied by an increase in the number of transmigrating melanoma cells, transmigration
assays were performed. Both TGF-β1 treatment and stimulation with B16/F10 ACM signifi-
cantly enhanced the number of transmigrating B16/F10 melanoma cells (40% and 46% more
transmigrating melanoma cells, respectively). Importantly, SB-431542 mitigated this increase
in transmigrating cells upon stimulation with B16/F10 ACM, indicating that the ACM induced
elevation in transmigrating cell numbers is TGF- β dependent (Fig. 5c).
6. Breast cancer cell line conditioned/activated medium induces TGF-β-
dependent EndMT in human umbilical vein endothelial cells
Next we sought to investigate whether cancer cells could induce EndMT features in other endo-
thelial cells as well. For this, HUVECs were subjected to stimulation with MDA-MB231 and
SK-BR3 human breast cancer cell line conditioned and activated medium. Stimulation of
HUVECs with either MDA-MB231 (Fig. 6a) or SK-BR3 (Fig. 6b) ACM, but not CM, resulted
TEER upon stimulation with either stimulus. The graph summarizes the results of 3 independent
measurements for each treatment, average and SE values are presented. Comparing the TEER between
TGF and control (*), ACM and control (*), TGF+SB and TGF (**), ACM+SB and ACM (***) we obtained
p<0.05 in all three time points, except for ACM vs. control at 2 hrs where the significance was lower (p<0.01,
****), as assessed by ANOVA and Bonferroni’s post hoc test. (b) TGF-β-dependent adhesion of B16/F10
melanoma cells to RBECs. Confluent RBECs were pretreated with TGF-β1, B16/F10 conditioned media
(B16 CM) or B16/F10 activated conditioned media (B16 ACM) in the presence or absence of SB-431542 (SB)
for 5 hrs. Fluorescently labeled B16/F10 melanoma cells (5x104/well) were plated onto confluent RBECs and
left for 70 min. After washing of non-adherent cells, attached melanoma cells were counted. TGF-β1
pretreatment led to a marked increase of melanoma cells attached to the endothelial monolayer. Similarly to
TGF-β1, B16/F10 ACM pre-treatment also enhanced the attachment of B16/F10 melanoma cells onto the
endothelial monolayer, in a TGF-β- dependent manner, since this effect was mitigated in the presence of the
TGF-β inhibitor SB-431542 (p<0.05 in case of TGF vs. control (*), B16 ACM vs. control (*) and B16 ACM
+SB vs. B16 ACM (**), as assessed by ANOVA and Bonferroni’s post hoc test). (c) Enhanced TGF- β-
dependent transendothelial migration of melanoma cells. RBECs were cultured until confluence in 12
well plates and treated with TGF-β1 or B16/F10 ACM for 5 hrs. Fluorescently labelled B16/F10 melanoma
cells (2 x 104/well) were plated onto the monolayer. Cells were monitored for 10 hrs and then transmigrating
melanoma cells were counted. Both stimuli enhanced the number of transmigrating melanoma cells.
Preincubation of RBECs with 10 μMSB-431542 for 60 min inhibited ACM induced transendothelial migration
of melanoma cells (*- p<0.01 for TGF vs. control and B16 ACM vs control, **- p<0.01 for B16 ACM+ SB vs.
B16 ACM, ANOVA and Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0119655.g005
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in SMA expression. SMA expression was mitigated in both cases in the presence of SB-431542,
indicating that these effects were TGF-β dependent.
7. Co-culture with melanoma cells leads to expressional changes
characteristic to EndMT in HUVECs
To investigate the direct effects of cancer cells on endothelial cells, we performed data mining in
publicly available expression profiling databases in the Gene Expression Omnibus (GEO) data-
base. We were searching for an experimental setup relevant to our studies. One such database con-
tained mRNA expression profiles of HUVECs and HUVECs co-cultured with 1205Lu human
metastatic melanoma cells. This experimental setup models the direct contact between endothelial
Fig 6. Activated breast cancer cell conditionedmedium induces SMA expression through TGF-β signaling in HUVECs. FBS-free M199 medium was
conditioned with MDA-MB231 (a) or SK-BR3 (b) human breast cancer cells for 24 hrs. A half of the conditioned media were subjected heat activation, and
then both conditioned (CM) and activated conditioned media (ACM) were supplemented with FBS. Cells were pre-treated with 10 μMSB-431542 for 60 min
and then treated with CM or ACM for 72 hrs, in the presence of the inhibitor. Samples were analyzed by Western blot. SB-431542 inhibited MDA-MB231 or
SK-BR3 ACM induced SMA expression. (c) Co-culture with melanoma cells leads to expressional changes characteristic to EndMT in HUVECs. Gene
expression profiles of HUVECs and HUVECs co-cultured with 1205Lu humanmetastatic melanoma cells were analyzed and compared. In HUVECs co-
cultured with melanoma cells there was a marked decrease in expression levels of several endothelial markers (KRT7, KRT18, TJP2), as well as a severe
decrease in FST expression. In parallel, co-cultured HUVECs exhibited elevated expression levels of EndMTmarkers (FN1, COL3A1, S100A4, MMP2,
COL1A2) and transcriptional regulators (ZEB1, Wnt5a, TWIST1, Snai2).
doi:10.1371/journal.pone.0119655.g006
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and melanoma cells occurring during circulating tumor cell arrest in the microvasculature. We
analyzed and compared mRNA expression levels for several additional EndMTmarkers.
In HUVECs co-cultured with melanoma cells there was a marked decrease in expression
levels of several endothelial markers (KRT7, KRT18, TJP2), as well as a severe decrease in FST
expression, an EMT/EndMT antagonist. Concomitantly, co-cultured HUVECs exhibited ele-
vated expression levels of EndMTmarkers (FN1, COL3A1, S100A4, MMP2, COL1A2) and
transcriptional regulators (ZEB1, Wnt5a, TWIST1, Snai2) (Fig. 5c).
These results indicate that the presence of melanoma cells in the co-culture induced expres-
sional changes in HUVECs characteristic to an EndMT.
Discussion
Prior to TEM, the first step of the extravasation process is the attachment of cancer cells to the
endothelial cells. The remodeling of endothelial cell contact protein expression is a prerequisite
for attachment between cancer and endothelial cells, EndMT ensuring the expression of cog-
nate ligands on endothelial cells which are already expressed by cancer cells. During EndMT
BECs lose their intercellular contacts, the expression levels of VE-cadherin, claudin-5 and
occludin being diminished or mitigated. The disruption of adherens and tight junctions be-
tween neighboring endothelial cells is an important step during TEM since endothelial cell
junction opening allows metastatic cells to squeeze between and pass through the endothelial
cell layer.
The down-regulation of endothelial cell contact proteins was accompanied by enhanced
N-cadherin, β1-integrin and fibronectin expression upon TGF-β1 treatment, this latter gain in
protein expression rendering the potential for endothelial cells to attach metastatic cells.
Cadherin switch is an essential step during EMT, when E-cadherin expression is depleted
and is followed by de novo expression of N-cadherin [25]. Since endothelial cells express low
levels of N-cadherin under control conditions [26], we couldn’t detect a cadherin switch; how-
ever in parallel with the decrease of VE-cadherin expression, we observed a marked increase in
N-cadherin expression upon EndMT of BECs. N-cadherin is also expressed by cancer cells and
it ensures the rolling and attachment of cancer cells to the endothelium [27, 28].
Integrins are a large family of heterodimeric cell adhesion molecules involved in cell-matrix
and cell-cell communications. Metastatic cancer cells express integrins, β1-integrin contribut-
ing to the adhesion between prostate cancer cells and endothelial cells through its ligand, fibro-
nectin [29]. Moreover, β1-integrin depletion reduced prostate cancer cell adhesion to
endothelial cells and fibronectin and reduced extravasation [30]. Fibronectin is a ligand for β1-
integrin. Endothelial β1-integrin expression in HUVECs is also required for metastatic cell ad-
hesion [31]. Since cancer cell β1-integrin is important for extravasation, the interaction and
attachment of cancer cells to endothelial cells require the presence of β1-integrin and fibronec-
tin on endothelial cells. BECs started expressing β1-integrin and fibronectin upon EndMT sug-
gesting that an EndMT is necessary for efficient cancer cell attachment and extravasation.
Rho GTPases are central regulators of EMT [32, 33, 34], EndMT [35] and of cancer cell ad-
hesion to endothelial cells [30, 36]. Endothelial cells undergo morphological changes and cyto-
skeletal remodeling during TEM. Endothelial RhoA is activated by lung cancer cell attachment
to brain endothelial cells and TEM, which leads to increased actomyosin contractility and actin
cytoskeleton reorganization in human brain microvascular endothelial cells [37]. Moreover, in-
hibition of the Rho/ROCK pathway prevents the disruption of tight junctions in brain endothe-
lial cells [22, 38]. Rho/ROCK is a well-known regulator of SMA expression during EMT and
EndMT [35]. BECs stimulated with TGF-β1 responded with calponin and ROCK-dependent
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SMA expression, rendering enhanced contractile properties corresponding to a myofibroblast-
like phenotype, contractility necessary for enabling TEM [39].
When tumor cell conditioned and activated medium was used for stimulation, RBECs ex-
pressed fibronectin and SMA, and lost claudin-5 expression in a TGF-β dependent manner, as
shown in our experiments. Moreover, both melanoma and breast cancer cell line conditioning
had similar effects on RBECs. These effects were not confined to BECs, since breast cancer cell
line conditioned and activated medium also induced SMA expression in HUVECs in a TGF-
β-dependent manner. TGF-β was responsible for the effects of the ACM, since ACM effects
could be inhibited using SB-431542, which exerts its effects on TGF-β1, TGF-β2 and TGF-β3
signaling. Another argument favoring the TGF-β- dependent effects of activated conditioned
media from tumor cells is that conditioning alone was not enough to induce EndMT. The
heat-activation step was necessary to obtain these effects, and it is well known that TGF-β can
be activated by heat or other stimuli. Moreover, ACM stimulation led to phosphorylation of
Smad2 and Smad3, a key step during TGF-β1- dependent signaling.
These results were in concordance with our findings in TEER and adhesion experiments.
Both stimuli (TGF-β1 treatments, as well as stimulation with tumor cell conditioned/activated
medium in a TGF-β dependent manner) induced a reduction in transendothelial resistance, a
prerequisite of the disruption of the endothelial layer. Both stimuli enhanced melanoma cell
adherence to the endothelial cells, the adherence of the tumor cells to the endothelial cells
being probably the first step before TEM. In parallel, and as a consequence of a decrease in
TEER and an increase in adhering melanoma cells, both stimuli led to an increase in melanoma
cells undergoing transendothelial migration.
TGF-β1 treatments and TGF-β in cancer cell conditioned medium were shown to regulate
adhesion between melanoma and endothelial cells, TGF-β1 inducing changes of endothelial
morphology [24]. Considering this along with our results on the expressional changes induced
TGF-β1 and cancer cell conditioned/activated medium in BECs and HUVECs, the endothelial
cell response enabling cancer cell TEM can be termed an endothelial-mesenchymal transition,
EndMT being a prerequisite for metastatic extravasation and TEM. Our findings suggest that
tumor cell extravasation takes place through a controlled process in which endothelial cells are
active facilitators as a consequence of their transition towards a myofibroblastic phenotype.
These results indicate that EndMT is one of the potential mechanisms occurring during the
complex phenomenon known as metastatic extravasation. During metastasis endothelial cells
undergo a rearrangement of cell surface and cell contact proteins, which would correspond to
the downregulation of the endothelial program and the activation of the fibroblastic program,
whereas the contractility would be conferred by the myogenic program of an EndMT. The
transition would not necessarily mean a full conversion into myofibroblastic phenotype, yet
the transition would confer the endothelial plasticity required to facilitate metastasis.
TGF-β has a dual role during metastatic progression: it induces the EMT of cancer cells
leading to the mobilization of the metastatic population, and it also “preconditions” certain en-
dothelial foci for extravasation through EndMT. Recently it was shown that an EndMT is re-
quired for intravasation as well [40], although its extent might be less dramatic since the new
blood vessels of the primary tumor vasculature are leaky and generally present weaker endothe-
lial cell-cell junctions [41]. An endothelial to mesenchymal transition-like process was de-
scribed in lymphendothelial cells during the intravasation of breast carcinoma cells involving
the function of EMT inducer ZEB1 [42]. EndMT may be an important step during metastatic
extravasation in organs where endothelial organization is more compact. The sinusoid capillar-
ies in the bone marrow [43] and as well as the capillaries of the liver [44] are lined with fenes-
trated endothelia, which present weaker, more permissive obstacles for the metastatic cells.
However, capillaries of other organs (lungs) and the endothelial cells of the BBB [45] are tightly
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compact, presenting a more restrictive environment for metastasis. Therefore infiltration of
metastatic cells into these tissues may require more specialized functions. EndMT induction
may be one of such functions along with other mechanisms, such as the release of proteolytic
enzymes such as seprase [18], which was found to be regulated by TGF-β as well [46].
There are two possible routes for metastatic cell-induced EndMT. First, metastatic cells, by
expressing TGF-β, could exert such an effect locally following an initial contact and a potential
weak adhesion step, or during circulating tumor cell arrest in the microvasculature [47]. This
latter possibility is being supported by the induction of EndMT during the direct contact be-
tween endothelial and melanoma cells in the co-culture experimental setup shown in Fig. 6c.
Yet it is important to mention, that in the context of EndMT such an initial weak adhesion
could potentially occur mainly through N-cadherin [27, 28], since E-selectin expression is in-
hibited by TGF-β1 [48]. The other potential mechanism is through a cumulative effect of TGF-
β expression and systemic release originating from the primary tumors. This latter possibility is
more plausible since some cancer cells were shown to migrate on the endothelium before
extravasation, a step that could allow finding the optimal sites for extravasation [49], an obser-
vation that could explain how this phenomenon unfolds in vivo. Indeed, factors expressed by
primary tumors can induce molecular changes in the endothelium before the homing of meta-
static cancer cells. Circulating metastatic cells can then later preferentially localize in regions of
vascular hyperpermeability [50]. When screening the endothelial wall for the metastatic site,
tumor cells screen for the least resistant endothelial point, and EndMT might be the mecha-
nisms leading to this lower resistance.
Current directions for developing therapeutic options to tackle metastatic disease focus
mainly on targeting the properties of the malignant cells. The proactive role played by the en-
dothelial cells during intravasation and extravasation could be exploited in the future to reduce
metastatic permeability of the endothelial cell barriers.
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